ABBV Jun 2024 165.000 call
| Previous Close | 7.40 |
| Open | 8.10 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 165.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 7.35 - 8.10 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2.04k |
ReutersAbbVie lifts profit forecast after Skyrizi sales beat expectations
(Reuters) -AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. Shares of AbbVie rose nearly 2.5% in premarket trading. The company now expects adjusted profit of between $11.13 and $11.33 per share for this year, compared with $10.97 to $11.17 estimated earlier.
- Reuters
AbbVie raises annual profit forecast on strong Skyrizi sales
AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. The company now expects adjusted profit of between $11.13 and $11.33 per share for this year, compared with $10.97 to $11.17 estimated earlier. Analysts on average expect annual profit of $11.10 per share, according to LSEG data.
PR NewswireAbbVie Reports First-Quarter 2024 Financial Results
AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2024.
